<DOC>
	<DOC>NCT02743871</DOC>
	<brief_summary>The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers who may be mildly atopic and in participants with chronic rhinosinusitis with nasal polyps</brief_summary>
	<brief_title>Study Of PF-06817024 In Healthy Subjects And In Patients With Chronic Rhinosinusitis With Nasal Polyps</brief_title>
	<detailed_description />
	<mesh_term>Polyps</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<criteria>Inclusion Criteria Healthy male subjects, healthy female subjects of nonchildbearing potential, 1855 years of age (Part 1) Male subjects, female subjects of nonchildbearing potential, female subjects of childbearing potential with documented bilateral tubal ligation (tubes tied) or bilateral salpingectomy (tubes removed), 1865 years of age, and 2 of the following symptoms: nasal congestion/obstruction, nasal discharge, face pain/pressure,or reduction/loss of smell (Part 2) Clinically significant diseases (cardiac, psychiatric, autoimmune, renal, etc.), positive urine drug test, fever within 7 days of dosing, active infections within 28 days of dosing (Part 1 and 2) History of allergic reaction to topical lidocaine, nasal surgery within 6 months (Part 2)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FIH, Pharmacokinetics</keyword>
</DOC>